[5-min read] 2024 was a long, strange trip.
[5-min read] Q&A with Kevin Matthews, Policy Director & Consultant
[5-min read] Beckley Psytech releases results from small trial of IV psilocin.
[4-min read] Q&A with Josh Kappel, Lawyer & Policymaker
[5-min read] Psilocybin helps healthcare workers recover from COVID burnout.
[4-min read] Q&A with Alexandra Plesner, Designer & Founder
[5-min read] Oregon Psilocybin Services’ first study could make sessions more affordable.
[5-min read] Q&A with Clementine Kruczynski, Researcher & Educator
[5-min read] Study shows doctors vastly overestimate their psychedelic knowledge.
[4-min read] Q&A with L. Alison McInnes, Psychiatrist & VP
[5-min read] Cybin's Phase 2 depression trial achieves a 100% response rate.
[5-min read] Q&A with Kat Murti, Activist & Director
